Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers

Chun Chia Cheng, Hsin Chi Lin, Kaun Jer Tsai, Ya Wen Chiang, Ken Hong Lim, Caleb Gon Shen Chen, Ying Wen Su, Cheng Liang Peng, Ai Sheng Ho, Ling Huang, Yu Cheng Chang, Huan Chau Lin, Jungshan Chang, Yi Fang Chang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The epidermal growth factor (EGF) receptor (EGFR) overexpressed in many cancers, including lung and head and neck cancers, and is involved in cancer cell progression and survival. PD-L1, increases in tumor cells to evade and inhibit CD8+ T cells, is a clinical immunotherapeutic target. This study investigated the molecular mechanism of EGF on regulating PD-L1 in EGFR-positive cancers and determined potential agents to reduce PD-L1 expression. RNA sequencing (RNAseq) and bioinformatics analysis were performed to determine potential driver genes that regulate PD-L1 in tumor cells-derived tumorspheres which mimicking cancer stem cells. Then, the specific inhibitors targeting EGFR were applied to reduce the expression of PD-L1 in vitro and in vivo. We validated that EGF could induce PD-L1 expression in the selected EGFR-positive cancers. RNAseq results revealed that STAT1 increased as a driver gene in KOSC-3-derived tumorspheres; these data were analyzed using PANTHER followed by NetworkAnalyst. The blockade of EGFR by afatinib resulted in decreased STAT1 and IRF-1 levels, both are transcriptional factors of PD-L1, and disabled the IFNr-STAT1-mediated PD-L1 axis in vitro and in vivo. Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis. These results indicate that EGF exacerbates PD-L1 by increasing the protein levels of STAT1 to enforce the IFNr-JAK1/2-mediated signaling axis in selected EGFR-positive cancers. The inhibition of EGFR by afatinib significantly reduced PD-L1 and may be a potential strategy for enhancing immunotherapeutic efficacy.

Original languageEnglish
Pages (from-to)1588-1598
Number of pages11
JournalMolecular Carcinogenesis
Volume57
Issue number11
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Epidermal Growth Factor Receptor
Epidermal Growth Factor
Neoplasms
RNA Sequence Analysis
Head and Neck Neoplasms
Lung Neoplasms
STAT1 Transcription Factor
Neoplastic Stem Cells
Computational Biology
Genes
Cell Survival
Phosphorylation
T-Lymphocytes

Keywords

  • afatinib
  • EGFR
  • lung cancer
  • PD-L1
  • STAT1

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers. / Cheng, Chun Chia; Lin, Hsin Chi; Tsai, Kaun Jer; Chiang, Ya Wen; Lim, Ken Hong; Chen, Caleb Gon Shen; Su, Ying Wen; Peng, Cheng Liang; Ho, Ai Sheng; Huang, Ling; Chang, Yu Cheng; Lin, Huan Chau; Chang, Jungshan; Chang, Yi Fang.

In: Molecular Carcinogenesis, Vol. 57, No. 11, 01.11.2018, p. 1588-1598.

Research output: Contribution to journalArticle

Cheng, CC, Lin, HC, Tsai, KJ, Chiang, YW, Lim, KH, Chen, CGS, Su, YW, Peng, CL, Ho, AS, Huang, L, Chang, YC, Lin, HC, Chang, J & Chang, YF 2018, 'Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers', Molecular Carcinogenesis, vol. 57, no. 11, pp. 1588-1598. https://doi.org/10.1002/mc.22881
Cheng, Chun Chia ; Lin, Hsin Chi ; Tsai, Kaun Jer ; Chiang, Ya Wen ; Lim, Ken Hong ; Chen, Caleb Gon Shen ; Su, Ying Wen ; Peng, Cheng Liang ; Ho, Ai Sheng ; Huang, Ling ; Chang, Yu Cheng ; Lin, Huan Chau ; Chang, Jungshan ; Chang, Yi Fang. / Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers. In: Molecular Carcinogenesis. 2018 ; Vol. 57, No. 11. pp. 1588-1598.
@article{1f5be890b8a646d3be42188088b8a720,
title = "Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers",
abstract = "The epidermal growth factor (EGF) receptor (EGFR) overexpressed in many cancers, including lung and head and neck cancers, and is involved in cancer cell progression and survival. PD-L1, increases in tumor cells to evade and inhibit CD8+ T cells, is a clinical immunotherapeutic target. This study investigated the molecular mechanism of EGF on regulating PD-L1 in EGFR-positive cancers and determined potential agents to reduce PD-L1 expression. RNA sequencing (RNAseq) and bioinformatics analysis were performed to determine potential driver genes that regulate PD-L1 in tumor cells-derived tumorspheres which mimicking cancer stem cells. Then, the specific inhibitors targeting EGFR were applied to reduce the expression of PD-L1 in vitro and in vivo. We validated that EGF could induce PD-L1 expression in the selected EGFR-positive cancers. RNAseq results revealed that STAT1 increased as a driver gene in KOSC-3-derived tumorspheres; these data were analyzed using PANTHER followed by NetworkAnalyst. The blockade of EGFR by afatinib resulted in decreased STAT1 and IRF-1 levels, both are transcriptional factors of PD-L1, and disabled the IFNr-STAT1-mediated PD-L1 axis in vitro and in vivo. Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis. These results indicate that EGF exacerbates PD-L1 by increasing the protein levels of STAT1 to enforce the IFNr-JAK1/2-mediated signaling axis in selected EGFR-positive cancers. The inhibition of EGFR by afatinib significantly reduced PD-L1 and may be a potential strategy for enhancing immunotherapeutic efficacy.",
keywords = "afatinib, EGFR, lung cancer, PD-L1, STAT1",
author = "Cheng, {Chun Chia} and Lin, {Hsin Chi} and Tsai, {Kaun Jer} and Chiang, {Ya Wen} and Lim, {Ken Hong} and Chen, {Caleb Gon Shen} and Su, {Ying Wen} and Peng, {Cheng Liang} and Ho, {Ai Sheng} and Ling Huang and Chang, {Yu Cheng} and Lin, {Huan Chau} and Jungshan Chang and Chang, {Yi Fang}",
year = "2018",
month = "11",
day = "1",
doi = "10.1002/mc.22881",
language = "English",
volume = "57",
pages = "1588--1598",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers

AU - Cheng, Chun Chia

AU - Lin, Hsin Chi

AU - Tsai, Kaun Jer

AU - Chiang, Ya Wen

AU - Lim, Ken Hong

AU - Chen, Caleb Gon Shen

AU - Su, Ying Wen

AU - Peng, Cheng Liang

AU - Ho, Ai Sheng

AU - Huang, Ling

AU - Chang, Yu Cheng

AU - Lin, Huan Chau

AU - Chang, Jungshan

AU - Chang, Yi Fang

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The epidermal growth factor (EGF) receptor (EGFR) overexpressed in many cancers, including lung and head and neck cancers, and is involved in cancer cell progression and survival. PD-L1, increases in tumor cells to evade and inhibit CD8+ T cells, is a clinical immunotherapeutic target. This study investigated the molecular mechanism of EGF on regulating PD-L1 in EGFR-positive cancers and determined potential agents to reduce PD-L1 expression. RNA sequencing (RNAseq) and bioinformatics analysis were performed to determine potential driver genes that regulate PD-L1 in tumor cells-derived tumorspheres which mimicking cancer stem cells. Then, the specific inhibitors targeting EGFR were applied to reduce the expression of PD-L1 in vitro and in vivo. We validated that EGF could induce PD-L1 expression in the selected EGFR-positive cancers. RNAseq results revealed that STAT1 increased as a driver gene in KOSC-3-derived tumorspheres; these data were analyzed using PANTHER followed by NetworkAnalyst. The blockade of EGFR by afatinib resulted in decreased STAT1 and IRF-1 levels, both are transcriptional factors of PD-L1, and disabled the IFNr-STAT1-mediated PD-L1 axis in vitro and in vivo. Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis. These results indicate that EGF exacerbates PD-L1 by increasing the protein levels of STAT1 to enforce the IFNr-JAK1/2-mediated signaling axis in selected EGFR-positive cancers. The inhibition of EGFR by afatinib significantly reduced PD-L1 and may be a potential strategy for enhancing immunotherapeutic efficacy.

AB - The epidermal growth factor (EGF) receptor (EGFR) overexpressed in many cancers, including lung and head and neck cancers, and is involved in cancer cell progression and survival. PD-L1, increases in tumor cells to evade and inhibit CD8+ T cells, is a clinical immunotherapeutic target. This study investigated the molecular mechanism of EGF on regulating PD-L1 in EGFR-positive cancers and determined potential agents to reduce PD-L1 expression. RNA sequencing (RNAseq) and bioinformatics analysis were performed to determine potential driver genes that regulate PD-L1 in tumor cells-derived tumorspheres which mimicking cancer stem cells. Then, the specific inhibitors targeting EGFR were applied to reduce the expression of PD-L1 in vitro and in vivo. We validated that EGF could induce PD-L1 expression in the selected EGFR-positive cancers. RNAseq results revealed that STAT1 increased as a driver gene in KOSC-3-derived tumorspheres; these data were analyzed using PANTHER followed by NetworkAnalyst. The blockade of EGFR by afatinib resulted in decreased STAT1 and IRF-1 levels, both are transcriptional factors of PD-L1, and disabled the IFNr-STAT1-mediated PD-L1 axis in vitro and in vivo. Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis. These results indicate that EGF exacerbates PD-L1 by increasing the protein levels of STAT1 to enforce the IFNr-JAK1/2-mediated signaling axis in selected EGFR-positive cancers. The inhibition of EGFR by afatinib significantly reduced PD-L1 and may be a potential strategy for enhancing immunotherapeutic efficacy.

KW - afatinib

KW - EGFR

KW - lung cancer

KW - PD-L1

KW - STAT1

UR - http://www.scopus.com/inward/record.url?scp=85052788348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052788348&partnerID=8YFLogxK

U2 - 10.1002/mc.22881

DO - 10.1002/mc.22881

M3 - Article

VL - 57

SP - 1588

EP - 1598

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 11

ER -